Andersen, Andreas
Knop, Filip Krag
Vilsbøll, Tina
Funding for this research was provided by:
Steno Diabetes Center Copenhagen, Gentofte
Article History
Accepted: 6 March 2021
First Online: 8 May 2021
Change Date: 14 May 2021
Change Type: Update
Change Details: Incorrect xml tagging
Declarations
:
: This article was supported by Novo Nordisk; the company was provided with the opportunity to perform a medical accuracy review.
: Andreas Andersen declares no conflicts of interest. Filip Krag Knop has served on scientific advisory panels and/or been part of speakers’ bureaus for, served as a consultant to, and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, and Zealand Pharma. Tina Vilsbøll has served on scientific advisory panels, been part of speakers’ bureaus for, served as a consultant to, and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, Mundipharma, MSD/Merck, Novo Nordisk, Sanofi, and Sun Pharmaceuticals.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: The authors directed the content and reviewed and critically revised all drafts.